STAT+: Psilocybin’s lasting benefits prove elusive in mice
Five Bay Area labs teamed up to compare lasting effects of psilocybin on anxiety and depression-like behavior in mice, with limited results:
UniQure announced the FDA accepted its AMT-130 gene therapy application for Huntington's disease treatment, with approval expected on May 1, 2027. The FDA is considering an advisory committee meeting to review the AMT-130 data. Meanwhile, a fertility treatment marketing itself as a biological clock reversal has created a global medical tourism industry, despite limited evidence to support its claims.
An eight-month STAT investigation uncovered clinics and intermediaries promoting mitochondrial replacement, or "three-parent IVF," to older women seeking genetically related children for tens of thousands of dollars. The piece continues in STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
